Publicacions en col·laboració amb investigadors/es de Hospital Universitario de Canarias (18)

2023

  1. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)

    Scientific Reports

  2. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  3. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

    Scientific reports, Vol. 12, Núm. 1, pp. 5289

  4. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

  5. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype

    Clinical and experimental rheumatology, Vol. 40, Núm. 4, pp. 727-733

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

2013

  1. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 7, pp. 1233-1238

2012

  1. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis

    Arthritis Research and Therapy, Vol. 14, Núm. 3

  2. Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279

  3. Influence of the IL6 gene in susceptibility to systemic sclerosis

    Journal of Rheumatology, Vol. 39, Núm. 12, pp. 2294-2302

  4. No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis

    Tissue Antigens, Vol. 80, Núm. 3, pp. 254-258

2011

  1. Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis

    Annals of the Rheumatic Diseases

  2. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology